Document link: Preliminary Recommendation on Pertuzumab for HER2+ breast cancer (Proponents may submit appeals to hta@doh.gov.ph until 04 February 2022.) Document Preview:
[Department Personnel Order No. 2021-3184] Appointment of the New Member of the Health Technology Assessment Council Subcommittee on Preventive and Promotive Health
Read more here: ALETH THERESE L. DACANAY, PH.D
HTAC Recommendation: COVID-19 Vaccine Sputnik V
The HTAC retains its recommendation for DOH to finance and include Sputnik V in the Philippine National Deployment and Vaccination Plan for COVID-19 for the general population aged 18 years and above. COVID-19 Vaccines under Emergency Use Authorization (EUA) The Food and Drug Administration (FDA) issues Emergency Use Authorization (EUA) for vaccines and drugs during public health emergencies which allows a continue reading : HTAC Recommendation: COVID-19 Vaccine Sputnik V
HTAC Recommendation: COVID-19 Vaccine Covovax
The HTAC recommends the DOH financing and inclusion of Covovax in the Philippine National Deployment and Vaccination Plan for COVID-19 (NDVP) for the general population aged 18 years and above. COVID-19 Vaccines under Emergency Use Authorization (EUA) The Food and Drug Administration (FDA) issues Emergency Use Authorization (EUA) for vaccines and drugs during public health emergencies which allows a shorter period continue reading : HTAC Recommendation: COVID-19 Vaccine Covovax
HTAC Recommendation: COVID-19 Vaccine Sinopharm
The HTAC recommends the DOH financing and inclusion of Sinopharm in the Philippine National Deployment and Vaccination Plan for COVID-19 Vaccines for the general population aged 18 years and above. COVID-19 Vaccines under Emergency Use Authorization (EUA) The Food and Drug Administration (FDA) issues Emergency Use Authorization (EUA) for vaccines and drugs during public health emergencies which allows a shorter period continue reading : HTAC Recommendation: COVID-19 Vaccine Sinopharm